This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

DIG trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The DIG trial investigated the role of cardiac glycosides in the treatment of patients with chronic heart failure and normal sinus rhythm.

Using a randomised, double-blind, placebo-controlled design, the trial measured the effect of digoxin on mortality and hospitalisation.

Patients with left ventricular ejection fractions of 0.45 or less were randomised to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors.

The median dose of digoxin was 0.25 mg per day. The mean follow-up was 37 months.

Reference:

  • 1) The Digitalis Investigation Group. (1997) The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. N Engl J Med, 336, 525-33.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.